Research suggests the use of non-steroidal anti-inflammatory drugs may mask the amount of sacroiliac joint inflammation found on MRI in patients with axial spondyloarthritis.
TLL-018, a Janus kinase 1/tyrosine kinase 2 inhibitor, proved more effective for treating patients with RA than tofacitinib, according to a study by Zeng et al.
How do inflammatory pathways strain the cardiovascular system? Dr. Mark Gorelik provided insights into the inflammatory processes that influence heart recovery after myocardial infarction, Kawasaki disease, multi-system inflammatory syndrome in children and more.
Recently, the Vasculitis Foundation, in collaboration with a group of physicians and vasculitis investigators in the U.S. and Latin America (i.e., Mexico, Colombia, Peru, Chile and Argentina), launched an educational series of videos in Spanish called, Aprendiendo de Vasculitis. “The goal of these videos is to provide education to all Spanish-speaking patients,” explains Sebastian E….
Resilience. That word has been living rent free in my head for the past three weeks. And rent free is a bit of understatement. It all began at the end of a very productive clinic, when the trainee and I sat down to discuss our reflections on the interactions with patients that we’d had in…
After intense academic classroom studies, University of Nebraska College of Medicine students in Omaha are able to put what they are learning in practice through the university’s Live Patient Experience (LPE) program, led by the Division of Rheumatology and Immunology. The LPE gives students real-life experience with patients and can serve as motivation to consider…
Guy Katz, MD, Joanna Marco, MD, & Jean Liew, MD, MS |
One of the most fun events at every annual meeting is the ACR Knowledge Bowl. In this quiz show-style trivia game, fellows form teams to compete for top prizes. There’s a charismatic host, a panel of esteemed judges and an auditorium packed with cheering spectators. Beyond the fun of competing against your peers from other…
Two ACR-led resolutions on in-office specialty drug dispensing and the proposed NIH Public Access Plan passed the House of Delegates and will become AMA policy.
In a clinical trial, patients with active systemic lupus erythematosus (SLE) did not experience a reduction in disease activity with the addition of rezpegaldesleukin to their standard treatments. However, some patient populations did see improvements in their disease activity compared with the placebo-treated group.